Treatments of Chronic Hepatitis C Genotype 1b with Oral Paritaprevir/Ritonavir/Ombitasvir+Dasabuvir or Daclatasvir/Asunaprevir: A Real-World Data from Taiwan

Abstract

Background: Hepatitis C Virus (HCV) genotype 1b is predominant in Taiwan. We report here using real-world data on a chronic HCV genotype 1b-infected patient given treatments of oral Pro-D or DAC/ASV. Methods: Data from subjects with chronic hepatitis C genotype 1b-infection undergoing DAAs therapy was retrospectively collected from October 2015 to January 2017. The DAAs regimens included a 12-week Pro-D and 24-week DCV+ASV. The therapeutic effectiveness and safety, including ALT, bilirubin, EOTVR and SVR at 12 weeks were all recorded. Results: Among all 81 subjects, 60 and 21 cases belonged to the Pro-D group and DCV/ASV group, with the rate of EOTVR and SVR12 being 98.3% and 90.5% respectively. Elevation of ALT was noted at the third month of DCV/ASV treatment, and increasing bilirubin was found at the secondary weeks of Pro-D treatment. Conclusion: Our study found SVR12 were 90.5% to 98.3% and 90.5%. Elevated liver function parameters were noted during the therapeutic period.